BL5923
CAS No. 921208-19-7
BL5923( BL 5923 | BL-5923 )
Catalog No. M16605 CAS No. 921208-19-7
BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBL5923
-
NoteResearch use only, not for human use.
-
Brief DescriptionBL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.
-
DescriptionBL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively; displays excellent selectivity against a panel of additional chemokine receptors including human CCR2, CCR4, CCR5, CCR6, CCR7, CXCR1, CXCR2, and CXCR3; suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse mode; ameliorates the progression of lupus nephritis in NZB/W mice; also improves survival, decreases the kidney fungal burden and protects from renal tissue injury in Candida-infected mice.
-
In Vitro——
-
In Vivo——
-
SynonymsBL 5923 | BL-5923
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number921208-19-7
-
Formula Weight487.956
-
Molecular FormulaC25H27ClFN3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(=O)NC1=CC(=C(C=C1C=CC(=O)N2CC3COCC(C2)N3CC4=CC=C(C=C4)F)OC)Cl
-
Chemical Name(E)-N-(5-chloro-2-(3-(9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-3-oxoprop-1-en-1-yl)-4-methoxyphenyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kitamura T, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8.
2. Revesz L, et al. Bridged piperazines and piperidines as CCR1 antagonists with oral activity in models of arthritis and multiple sclerosis. Lett Drug Des Discov. 2006;3:689–694.
3. Bignon A, et al. J Immunol. 2014 Feb 1;192(3):886-96.
4. Lionakis MS, et al. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02365-16.
molnova catalog
related products
-
CXCR2-IN-1
A potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6.
-
BMS-22
A potent, selective, allosteric CCR2 antagonist with binding IC50 of 5.1 nM.
-
INCB9471
A potent, selective and orally bioavailable CCR5 antagonist IC50 of 6.5 nM, Kd of 3.1 nM in human PBMCs.
Cart
sales@molnova.com